Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Smoking Cessation 1 Renal Insufficiency 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia 1 Hepatitis B 1 Hematuria 1 Fatigue 1 Carcinoma, Transitional Cell 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Trastuzumab 628 Paclitaxel 577 Cyclophosphamide 555 Docetaxel 485 Capecitabine 402 Letrozole 376 Fulvestrant 327 Doxorubicin 294 Carboplatin 279 Tamoxifen 275 Anastrozole 243 exemestane 228 Radiotherapy 218 Epirubicin 211 Bevacizumab 196 palbociclib 189 pertuzumab 186 Vinorelbine 167 Lapatinib 167 Gemcitabine 166 pembrolizumab 162 Surveys and Questionnaires 139 Exercise 136 Magnetic Resonance Spectroscopy 123 Fluorouracil 119 Blood Specimen Collection 118 eribulin 117 Albumin-Bound Paclitaxel 117 Drug Therapy 111 130-nm albumin-bound paclitaxel 111

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × Urinalysis × Clear all

NCT00519168 2017-10-06

Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival

Stanford University

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡